BTRC and plasma cell myeloma: Importantly, we also demonstrate an anti-tumor efficacy of PDTC, a small-molecule that has been reported to inhibit β-TrCP E3 ubiquitin ligase activity [50] in the well-established preclinical 5TGM1 mouse model of multiple myeloma that has been shown in the past to be predictive of drugs with clinical utility.